Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Animal Health UK Grants Approval for Boehringer’s BTV-3 Livestock Vaccine
vet

UK Grants Approval for Boehringer’s BTV-3 Livestock Vaccine

24th December 2024

Boehringer Ingelheim has secured a permit from the UK’s Department for Environment, Food & Rural Affairs (DEFRA) for its new bluetongue virus serotype 3 (BTV-3) vaccine, BULTAVO 3™. This development is set to bolster the defence against recent BTV-3 outbreaks threatening sheep and cattle across Europe, including Britain. Implemented initially in high-risk areas, this vaccine marks a significant step in safeguarding both the health of livestock and the economic stability of farmers.

The approval of BULTAVO 3™ underscores Boehringer Ingelheim’s proactive response to combating the swift spread of BTV-3—a midge-transmitted virus that emerged in the Netherlands in 2023 and has since jeopardised over 5,000 livestock farms. Recognised as a notifiable disease in the UK, the presence of BTV-3 necessitates immediate reporting to authorities to prevent severe clinical damage and mortality among livestock. Boehringer collaborated with Bioveta to accelerate the vaccine’s development, offering robust immunity for sheep after a single dose and cattle after two doses, thus addressing a critical need in the livestock industry.

The introduction of BULTAVO 3™ offers a promising solution to shield livestock from the devastating impact of BTV-3. By enabling early intervention in high-risk areas, Boehringer Ingelheim aims to assist farmers in preserving their herds and ensuring agricultural stability. This advancement bodes well for future containment of BTV-3, providing both peace of mind and economic assurance to the farming community.

Contact Poppy for more details.

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.